Published TCIMAIL newest issue No.189. | Various analytical charts can be searched on each product detail page and Product Document Search. (The kinds of analytical charts differ by product.)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 167221-71-8 | Product Number: C3503
Clevidipine
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 3-[(Butyryloxy)methyl] 5-Methyl 4-(2,3-Dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
- 4-(2,3-Dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic Aicd 3-[(Butyryloxy)methyl] 5-Methyl Ester
Documents:
| Size | Unit Price | Hyderabad | Chennai | Japan* | Quantity |
|---|---|---|---|---|---|
| 250MG |
₹4,800
|
Contact Us | Contact Us | Contact Us |
|
| 1G |
₹9,200
|
Contact Us | Contact Us | 11 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day & Chennai stocks will be dispatched in 3-6 working days.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*Change currency to place order in USD.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | C3503 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__2__3Cl__2NO__6 = 456.32 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | 0-10°C |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 167221-71-8 |
| Reaxys Registry Number | 8450029 |
| PubChem Substance ID | 354335546 |
| Merck Index (14) | 2352 |
| MDL Number | MFCD00940070 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 96.0 % |
| Melting point | 141.0 to 145.0 °C |
Properties (reference)
| Melting Point | 143 °C |
| Solubility in water | Insoluble |
| Degree of solubility in water | 0.1 g/l |
GHS
Related Laws:
Transport Information:
Application
Clevidipine: An Ultrashort-Acting 1,4-Dihydropyridine L-Type Calcium Channel Antagonist
Clevidipine is an ultrashort-acting L-type calcium channel antagonist with selectivity for arteriolar vasodilatation. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Clevidipine particularly induce a relaxation of the muscle in arterial bed, and reduces arterial blood pressure by decreasing systemic vascular resistance directly. On the other hand, clevidipine does not reduce cardiac filling pressure, confirming lack of effects on the venous vessels. Clevidipine is a 1,4-dihydropyridine calcium channel antagonist, structurally related to felodipine [F0814]. (The product is for research purpose only.)
References
- In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man
- Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs
- Clevidipine. A review of its use in the management of acute hypertension
- Determination of an ultrashort-acting antihypertensive dihydropyridine, clevidipine, in blood using capillary gas chromatography-mass spectrometry and of the primary metabolite using liquid chromatography and fluorescence detection
- Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients
PubMed Literature
Articles/Brochures
TCIMAIL
Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number
Incorrect Lot Number is entered
The requested analytical chart is not available. Sorry for the inconvenience.